Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Synthego

Synthego raises $200M Series C at $1.2B valuation

$200M
Total Raised
Series C
Latest Round
2012
Founded
200+
Employees
3565 Haven Avenue, Redwood City, CA 94063
1 min read

Quick Facts

Valuation
$1.2B
Latest Round Size
$200M
Latest Round Date
June 2024

Synthego: Series C Funding Round

Synthego has successfully raised $200M in Series C funding, reaching a valuation of $1.2B.

Company Overview

CRISPR genome engineering tools

Funding Details

The Series C round was led by Founders Fund, with participation from 8VC, Menlo Ventures, Paladin Capital Group, Tencent.

Company Information

  • Headquarters: 3565 Haven Avenue, Redwood City, CA 94063
  • Founded: 2012
  • Employees: 200+
  • Category: Biotech

Investment

Synthego plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Founders Fund: Verified investor in Series C
  • 8VC: Verified investor in Series C
  • Menlo Ventures: Verified investor in Series C
  • Paladin Capital Group: Verified investor in Series C
  • Tencent: Verified investor in Series C

Key Investors

Founders Fund
Lead Investor
Verified investor in Series C
8VC
Investor
Verified investor in Series C
Menlo Ventures
Investor
Verified investor in Series C
Paladin Capital Group
Investor
Verified investor in Series C
Tencent
Investor
Verified investor in Series C

Topics

verified(3079)real-funding(3079)series-c(264)synthegobiotech3565-haven-avenue

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M